This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

- 1. (Currently Amended) A fusion protein comprising a heterologous polypeptide fused to at least a portion of a variant of a wild type major coat protein of a virus selected from the group consisting of a filamentous phage, a lambda phage, a Baculovirus, a T4 phage and a T7 phage.
 - 2. (Canceled)
- 3. (Currently Amended) The fusion protein of claim 1, wherein the virus is a filamentous phage, the wild type major coat protein is gpVIII and the heterologous polypeptide is fused to the N-terminus or the C-terminus thereof.
- 4. (Currently Amended) The fusion protein of claim 1, wherein the variant of a wild type major coat protein is a filamentous phage coat protein variant which contains at least one amino acid residue selected from the list below in the position indicated:

Residue Number	Amino Acid Residue
1	E, L, V, Q, D, I, N
2	R, H, F, W, E, K, Y, D
3	T, E, L, S, D, I, V, A
4	D, R, H, E, K
5	R, H, N, D, K, Q, E
6	Y, W, S, I, L, F, T, V
7	T, N, S
8	D, H, R, E, K
9	E, Q, T, D, N, S
11	W, I, V, Y, L, F
12	R, H, N, E, D, K, Q

U.S. Patent Application Serial No. 09/380,447 Amendment Under 37 C.F.R. § 1.116 dated November 13, 2006 Reply to Final Office Action of September 13, 2006

13	I, L, E, Q, A, V, D, T, N, S
14	L, I, V
15	D, R, N, E, K, H, Q
16	E, V, L, F, D, I, A, S, G
17	E, V, L, I, A, T, D
18	L, V, I
19	L, T, Q, E, I, V, S, A, N, D
20	R, D, H, N, Q, K, E
21	W, Y, I, L, F, V
22	W, F, Y
23	W, Y, I, V, H, K, F, L, R
24	I, Q, L, N, V
25	S, L, I, T, V
26	A, I, V, G, L, M
27	N, T, S
28	I, L, V
29	K, R, F, W, H, Y
30	I, V, L

5-6. (Canceled)

- 7. (Original) The fusion protein of claim 1, wherein the variant has 2 50 altered residues relative to the wild type coat protein sequence.
- 8. (Original) The fusion protein of claim 1, wherein the heterologous polypeptide is an antibody or a fragment thereof or a cytokine or a cytokine receptor.
- 9. (Original) A replicable expression vector comprising a gene fusion, wherein the gene fusion encodes the fusion protein of claim 1.

U.S. Patent Application Serial No. 09/380,447 Amendment Under 37 C.F.R. § 1.116 dated November 13, 2006 Reply to Final Office Action of September 13, 2006

- 10. (Canceled)
- 11. (Previously Presented) Host cells comprising the vector of claim 9.
- 12. (Previously Presented) A virus particle displaying the fusion protein of claim 1 on the surface thereof.

13-28. (Canceled)

- 29. (Currently Amended and Withdrawn) The fusion protein of claim 1, wherein <u>the</u> heterologous <u>protein polypeptide</u> comprises at least one amino acid substitution in one or more regions of the molecule.
- 30. (Currently Amended) The fusion protein of claim 1 wherein the filamentous phage is selected from the group consisting of Ff, Ike, If1, Pf1, Pf3, Xf, fd, f1, zj-2, I2-2 and M13.
- 31. (Currently Amended) The fusion protein of claim 1, wherein the filamentous phage wild type coat protein is selected from the group consisting of SEQ ID NOS: 2, 3, 4, 5, 6, 7 and 8.
- 32. (Previously Presented) The fusion protein of claim 1, wherein the filamentous phage coat protein is a hyper-functional variant of the major coat protein that increases the number of fusion proteins incorporated into a virus particle.
- 33. (Previously Presented) The fusion protein of claim 1, wherein the filamentous phage coat protein variant is a hypo-functional variant of the major coat protein that decreases the number of fusion proteins incorporated into a virus particle.

34-43. (Canceled)

- 44. (Currently amended) The fusion protein of claim 1, wherein the heterologous polypeptide is separated from the <u>variant</u> wild type major coat protein by a linking peptide.
- 45. (Previously Presented) The fusion protein of claim 44, wherein the linking peptide is selected from the group consisting of SEQ ID NO:110, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:118, SEQ ID NO:134, SEQ ID NO:136, SEQ ID NO:138, SEQ ID NO:193, SEQ ID NO:195, SEQ ID NO:197, SEQ ID NO:199, SEQ ID NO:201, SEQ ID NO:203, SEQ ID NO:205, SEQ ID NO:207, SEQ ID NO:209, SEQ ID NO:211, SEQ ID NO:213, SEQ ID NO:215, SEQ ID NO:217, SEQ ID NO:219, SEQ ID NO:221, SEQ ID NO:223, SEQ ID NO:225, SEQ ID NO:227, SEQ ID NO:229, SEQ ID NO:231, SEQ ID NO:233, SEQ ID NO:235, SEQ ID NO:237, SEQ ID NO:239, SEQ ID NO:241, SEQ ID NO:243, SEQ ID NO:245, SEQ ID NO:247, SEQ ID NO:249, SEQ ID NO:251, SEQ ID NO:253, SEQ ID NO:255, SEQ ID NO:257, SEQ ID NO:259, SEQ ID NO:261, SEQ ID NO:263 and SEQ ID NO:265.
- 46. (Previously Presented) The fusion protein of claim 8, wherein the heterologous protein is an antibody or a fragment thereof.
- 47. (Previously Presented) The fusion protein of claim 46, wherein the antibody binds to a target selected from the group consisting of, cytokines, cytokine receptor superfamily receptors, hematopoietic growth factor superfamily receptors, human leukocyte surface markers, prolactin receptors, growth hormone receptors, ciliary neurotrophic factor receptors, C-Mpl receptors, erb2, erb3, erb4, IL-10, IL-12, IL-13 and IL-15.
- 48. (Withdrawn) The fusion protein of claim 47, wherein the human leukocyte surface marker is selected from the group consisting of CD1a-c, CD2, CD2R, CD3-CD10, CD11a-c, CDw12, CD13, CD14, CD15, CD15s, CD16, CD16b, CDw17, CD18-C41, CD42a-d, CD43, CD44, CD44R, CD45, CD45A, CD45B, CD45O, CD46-CD48, CD49a-f, CD50-CD51, CD52, CD53-CD59, CDw6O, CD61, CD62E, CD62L, CD62P, CD63, CD64, CDw65, CD66a-e, CD68-CD74, CDw75, CDw76, CD77, CDw78, CD79a-b, CD80-CD83, CDw84, CD85-CD89,

5

CDw90, CD91, CDw92, CD93-CD98, CD99, CD99R, CD100, CDw101, CD102-CD106, CD107a-b, CDw108, CDw109, CD115, CDw116, CD117, CD119, CD120a-b, CD121a-b, CD122, CDw124, CD126-CD129, and CD130.

49. (Withdrawn) The fusion protein of claim 47, wherein the cytokine receptor superfamily receptor is selected from the group consisting of IL-2b, IL-2g, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, erythropoetin, leukemia inhibitory factor, and oncostatin M.

50-51. (Canceled)

52. (Withdrawn) The fusion protein of claim 4, wherein the major coat protein variant contains at least one amino acid residue selected from the list below in the position indicated:

Residue Number	Amino Acid Residue
1	D, I
2	K, Y
3	S
4	E
5	K
6	F
7	A, S
8	R,K
9	D, A

53. (Withdrawn) The fusion protein of claim 4, wherein the major coat protein variant contains at least one amino acid residue selected from the list below in the position indicated:

Residue Number	Amino Acid Residue
11	Y

U.S. Patent Application Serial No. 09/380,447 Amendment Under 37 C.F.R. § 1.116 dated November 13, 2006 Reply to Final Office Action of September 13, 2006

12	E
13	A
14	L
15	Е
16	D
17	I
18	I, A
19	T
20	N

54. (Withdrawn) The fusion protein of claim 4, wherein the major coat protein variant contains at least one amino acid residue selected from the list below in the position indicated:

Residue Number	Amino Acid Residue
21	Y, L
22	F, I
23	F, R
24	L
25	L
26	G
27	T
28	V, M
29	Y
30	V

55. (Previously Presented) The fusion protein of claim 1, wherein the variant of the wild type major coat protein has at least one amino acid substitution.

- 56. (Currently amended) The fusion protein of claim 1, wherein the variant of the wild type major coat protein has at least 8 amino acid[[s]] substitutions corresponding to amino acid positions 1, 2, 3, 4, 5, 6, 8, and 9 of protein VIII.
- 57. (Currently amended) The fusion protein of claim 1, wherein the variant of the wild type major coat protein has at least 7 amino acid[[s]] substitutions corresponding to amino acid positions 11, 12, 13, 15, 17, and 20 of protein VIII.
- 58. (Currently amended) The fusion protein of claim 1, wherein the variant of the wild type major coat protein has at least 10 amino acid[[s]] substitutions corresponding to amino acid positions 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30 of protein VIII.